JESSE GOODMAN - 23 Jun 2021 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
Director
Signature
/s/Jose E. Rivera, Attorney-In-Fact
Issuer symbol
NTLA
Transactions as of
23 Jun 2021
Net transactions value
$0
Form type
4
Filing time
25 Jun 2021, 18:08:30 UTC
Next filing
16 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Award $0 +2,094 $0.000000 2,094 23 Jun 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NTLA Stock Option (right to buy) Award $0 +3,382 $0.000000 3,382 23 Jun 2021 Common Stock 3,382 $83.59 Direct F2
holding NTLA Stock Option (right to buy) 38,000 23 Jun 2021 Common Stock 38,000 $18.52 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2 This option was granted on June 23, 2021 with respect to 3,382 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.
F3 As was previously reported, this option was granted on October 29, 2018 with respect to 38,000 shares of Common Stock, with 33% vesting on October 29, 2019 and the remaining 67% vesting in eight substantially equal quarterly installments thereafter.
F4 The expiration date of the reported grant was mistakenly reported in a Form 4 filed on 10/31/2018 as 10/28/2018.